PMV Pharmaceuticals (PMVP) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 5, 2025, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 4, 2025, 11:59 PM ET.

Voting matters and shareholder proposals

• Election of two Class II directors: Arnold Levine, Ph.D., and Charles M. Baum, M.D., Ph.D.

• Advisory vote on the compensation of named executive officers.

• Ratification of Ernst & Young LLP as the independent public accounting firm.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Board nominees for Class II director positions are presented for election at the annual meeting.